Immunoassays are essential tools in evaluating the success of a vaccine by measuring immune responses to the inoculated antigen. These tests, which include techniques like enzyme-linked immunosorbent assays (ELISA), neutralization assays, and flow cytometry, help quantify the levels of antibodies and other immune markers that are produced after vaccination. By assessing the presence and strength of these immune responses, immunoassays offer insights into the effectiveness of a vaccine in preparing the immune system for future pathogen exposure. Additionally, these tests are critical in determining the need for booster shots and evaluating vaccine safety by detecting any adverse immune reactions. Immunoassays also play a vital role in the clinical development of vaccines, helping researchers determine the optimal vaccine dosage and the immune response timeline, ensuring that the vaccine provides long-lasting protection and is suitable for widespread use.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey